Lumber Liquidators Lawsuits

Gilman Law LLP, a leading national law firm with over 40 years of experience protecting the rights of

shareholders and consumers, is continuing its investigation into reports that laminate flooring sold by

Lumber Liquidators and installed in millions of homes across the country is contaminated with

dangerous amounts of formaldehyde. The Firm has already filed a Lumber Liquidators lawsuit that,

among other things, claims the Company’s directors failed to comply with their fiduciary duties in

connection with applicable laws and regulations pertaining to formaldehyde emissions from composite

wood products. Gilman Law LLP is also offering free Lumber Liquidators lawsuit evaluations.

Lumber Liquidators is the nation’s largest retailer of hardwood flooring, the Company and its investors

stand to incur significant damages as a result of the concerns surrounding the Company’s laminate

flooring products. If you are among them, please contact Gilman Law LLP today to learn more about

filing a Lumber Liquidators lawsuit.

Gilman Law Fiduciary Duty Lawsuit

In March 2015, Gilman Law LLP filed a Lumber Liquidators derivative lawsuit against the Company’s

board of directors, including former CEO Robert Lynch, for allegedly breaching their fiduciary duties in

connection with their failure to oversee the operations of the Company as they relate to the

manufacture and sale of their wood laminate products, as well as the import and trade of illegally

sourced lumber from the Russian Far East in violation of the Lacey Act. In addition, the complaint

challenges the alleged unlawful insider selling of tens of millions of dollars of Lumber Liquidators stock

by certain members of the Board during a time when the stock was allegedly inflated due to a failure of

the Company’s management to properly disclose the activities of and accurate financial information

regarding the Company. The complaint, which is currently pending in Delaware Court of Chancery,

seeks damages on behalf of the Company arising from and incurred and to be incurred in connection

with pending federal securities lawsuits, consumer product liability lawsuits, and investigations by

various federal agencies, including arms of the U.S. Department of Justice.

Lumber Liquidators Products Liability Lawsuits

Lumber Liquidators has been named a defendant in dozens of product liability lawsuits involving its

laminate flooring products. This litigation began to grow after 60 Minutes aired a report focusing on the

excessive formaldehyde levels contained in certain laminate flooring Lumber Liquidators purchased

from manufacturers in China. Among other things, the report noted that certified testing of laminate

wood flooring purchased from Lumber Liquidators locations in Virginia, Florida, Texas, Illinois, and New

York revealed levels of formaldehyde that exceed those permitted by the California Air Resources Board

(CARB). In addition, 60 Minutes reported that employees at certain Chinese manufacturers “openly

admitted” that they use materials with higher levels of formaldehyde and falsely label Lumber

Liquidators’ laminate flooring as “CARB Phase 2 Compliant.”

At low levels, formaldehyde exposure can cause a number of serious health problems, including

respiratory issues, asthma, and irritation of the eyes, nose and throat. Higher levels of formaldehyde

have been linked to various types of cancer, including myeloid leukemia and nasopharyngeal cancer. 60

Minutes noted that children may be more susceptible to formaldehyde-related health issues, as they are

more likely to come into close contact with the Lumber Liquidators flooring.

Lumber Liquidator Lawsuit Reviews

For a no-obligation evaluation of your potential case, please fill out our free consultation form or call

Gilman Law LLP direct to speak with one of our attorneys at (888) 252-0048.

Gilman Law LLP Announces Continued Prosecution of Transvaginal Mesh Lawsuits and Verdict of $100 Million

Gilman law is continuing to prosecute transvaginal mesh cases for women who have suffered debilitating transvaginal mesh complications following surgery to repair pelvic organ prolapse or stress

urinary incontinence.

A state court jury found yesterday that Boston Scientific’s Pinnacle and Advantage Fit inserts, built to

buttress sagging organs and treat incontinence in women, were defectively designed and that Boston

Scientific engaged in fraudulent concealment by failing to alert doctors and patients to the devices’ faulty design. The

jury awarded $100 million to a 51-year-old woman whose mesh eroded after it was implanted leaving

her with a scarred vagina and additional medical problems.

Boston Scientific, a Marlborough, Massachusetts-based company, agreed last month to settle a small amount of claims for

$119 million, based upon systemic damages for claims where inserts damaged women’s organs and

made sexual intercourse painful.

According to Gilman Law LLP, a leading pharmaceutical law and defective medical device plaintiffs’ law firm

that is currently representing women in transvaginal mesh lawsuits, serious settlement talks reportedly are now

underway to resolve this massive litigation.

On June 2, 2015, the Court will convene a joint status conference, as well as individual meetings with six

of the seven defendants – American Medical Systems, Boston Scientific, C.R. Bard, Coloplast, Cook

Medical and Ethicon – with the goal of moving closer to resolution.

Women who have received these devices may be at risk for a number of very serious and painful

complications, including:

• Mesh erosion through the vaginal tissue, possibly causing the skin to split
• Mesh extrusion and exposure.
• Perforation or puncture of bladder, intestines, bowels, and/or vaginal wall
• Protrusion or lump in the vaginal opening
• Recurrence of pelvic organ prolapse
• Recurrence of stress urinary incontinence
• Urinary problems
• Vaginal bleeding, pain and discomfort, chronic drainage, discharge, infections, scarring and/or shrinkage
• Painful sexual intercourse

Gilman Law LLP is providing complimentary lawsuit consultations to women who suffered severe

complications, including tremendous pain and suffering, following implantation of transvaginal mesh.

For more information, please contact Gilman Law LLP today by visiting our website, www.gilmanlawllp.com, to fill out a free, no obligation case evaluation form, or call Toll Free at 1-888-

252-0048.

About Gilman Law LLP

Gilman Law LLP, a leading pharmaceutical law and defective drug law firm, has been recognized for

delivering successful results to their clients across a broad range of claims stemming from consumer

product injury, mass tort, and class action lawsuits. For over 35 years, the Gilman Law LLP team of highly

experienced lawyers has earned renown for tireless work on behalf of their clients on many of today’s

most challenging and important legal issues.

Contact:
Kenneth G. Gilman
Gilman Law LLP
8951 Bonita Beach Road, S.E. Suite #525
Bonita Springs, FL 34135-4208
1-888-252-0048
kgilman@gilmanlawllp.com

Gilman Law LLP Investigating Zofran Birth Defect Lawsuits

Gilman Law LLP, a leading pharmaceutical law and defective medical device plaintiffs’ law firm, is now investigating potential Zofran birth defect lawsuits on behalf of children who were born with serious congenital defects, allegedly due to their mothers use of Zofran during the first trimester of pregnancy.

Zofran is not approved by the U.S. Food & Drug Administration (FDA) to treat morning sickness or hyperemesis gravidarum. However, a report published in the August 2014 issue of the American Journal of Obstetrics and Gynecology found that about 1 million pregnant women per year are exposed to Zofran or generic versions of ondansetron for this purpose.

Gilman Law LLP is seeking to hear from parents and caregivers of children who may have sustained any of the following birth defects due to prenatal Zofran exposure:

Zofran Birth Defects Lawsuit

• Heart defects, including septal defects (holes in the heart)
• Cleft lip and cleft palate
• Club foot
• Skull deformities (craniosynostosis)
• Musculoskeletal Defects
• Fetal growth restriction (poor growth in the womb)
• Kidney defects
• Hydronephrosis
• Hypospadia

Alleged victims of Zofran-related birth defects may be entitled to significant financial compensation from GlaxoSmithKline. However, potential claimants should be aware that all personal injury claims, including those involving Zofran, are subject to strict statutes of limitations that vary by state. Individuals seeking to file suit against GlaxoSmithKline are urged to contact Gilman Law LLP today, TOLL FREE at 888-252-0048, to ensure that their right to recovery is not placed in jeopardy.

Zofran is currently approved by the U.S. Food & Drug Administration (FDA) to treat nausea and vomiting related to chemotherapy, radiation treatments and surgery. The drug is listed by the agency in Pregnancy Category B, which indicates it has not been well studied for use in pregnancy.

In 2012, Glaxo resolved criminal and civil charges over the marketing of several drugs, including Zofran, and paid $3 billion as part of a settlement with the U.S. Department of Justice. Among other things, the company had been accused of promoting the use of Zofran as a treatment for morning sickness, even though it had not been approved for this purpose by the FDA.

Court documents indicate that more than a half dozen Zofran birth defect lawsuits have been filed in U.S. courts since February, all of which accuse GlaxoSmithKline of fraudulently marketing the medication as a safe and effective treatment for morning sickness. Most recently, a complaint was filed in the U.S. District Court, Eastern District of Arkansas, on behalf of a child who was born with a partial cleft lip after his mother took Zofran to control nausea and vomiting during her first trimester. Like similar complaints filed in recent months, the lawsuit accuses GlaxoSmithKline of concealing hundreds of reports linking Zofran to birth defects from regulators, doctors and patients. The complaint also notes that a number of studies have suggested that exposure to Zofran during the first trimester of pregnancy increases the likelihood for birth defects, including a 2.37 times increased risk of cleft palate; 2 times increased risk of a heart defect; and 20 percent increased risk of any birth defect. (Case No. 15-284)

Gilman Law LLP is providing complimentary Zofran lawsuit consultations to families who believe their baby was harmed by this drug. For more information, please contact Gilman Law LLP today by visiting our website, www.gilmanlawllp.com, to fill out a free, no obligation case evaluation form, or call Toll Free at 1-888-252-0048.

About Gilman Law LLP
Gilman Law LLP, a leading pharmaceutical law and defective drug law firm, has been recognized for delivering successful results to their clients across a broad range of claims stemming from consumer product injury, mass tort, and class action lawsuits. For over 40 years, the Gilman Law LLP team of highly experienced lawyers has earned renown for tireless work on behalf of their clients on many of today’s most challenging and important legal issues.

Contact:

Gilman Law LLP

8951 Bonita Beach Road, S.E. Suite #525

Bonita Springs, FL 34135-4208

1-888-252-0048

kgilman@gilmanlawllp.com